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Introduction:
 
 Health-related quality-of-life (HRQL) can
be defined as the impact of disease and treatment across
the physical, psychological, social and somatic domains
of functioning and well-being. Health-related quality-
of-life measures are included in clinical trials of drug
treatment to assess the impact of therapy on the pa-
tient’s functioning. HRQL guidance could allow for use
of this data in drug labeling and promotion.
 
Objectives:
 
 The aim of our study was to provide rec-
 
ommendations with respect to regulatory issues im-
portant to the development of guidelines for HRQL re-
search.
 
Methods:
 
 The HRQL workshop was planned jointly by
members of the Pharmaceutical Research and Manufac-
turers of America Health Outcomes Committee and the
Division of Drug Marketing, Advertising, and Commu-
nications of the Food and Drug Administration. The
workshop was limited to six regulatory issues related to
HRQL research in clinical trials of pharmaceutical ther-
apies. These six issues were: instrument selection and
validation, study design, data analysis, HRQL and
safety, clinical meaning, and promotional use. Before
the meeting, a consensus was reached that HRQL does
not measure, nor should it be used to measure, safety.
Therefore, five work groups discussed HRQL issues
and made recommendations.
 
Results:
 
 Overall, the workshop recommended that HRQL
measures be treated as any other clinical end point. The
workshop recognized that research in HRQL methods
is ongoing and that any guidance should be flexible to
allow for changes in this developing research area.
 
Conclusions:
 
 HRQL provides a patient perspective on
the impact of disease and therapy on patients’ daily life
and functioning. Including HRQL information in pro-
motion could be beneficial to decision making on the
use of therapies. HRQL is a measure of effectiveness,
not safety, and should be treated as any other clinical
end point.
 
Keywords:
 
 guidance, outcomes research, quality-of-life
research, regulatory.
 
Introduction
 
This paper is a summary of a workshop held on
March 24 and 25, 1999, at which regulatory is-
sues for health-related quality of life (HQRL) were
discussed. This summary reflects the viewpoints of
workshop participants and as such is not intended
to reflect FDA policy, nor is it a consensus of the
field of health-related quality of life.
Health-related quality-of-life measures are more
and more frequently included in clinical trial assess-
ments of drug treatment. These patient-reported
outcome measures are often assessed in addition
to more traditional clinical measures such as blood
pressure, cholesterol, morbidity events, and phy-
sician-based disease assessments. Implicit in the
use of patient-reported outcome measures such as
HRQL is the concept that pharmaceutical inter-
ventions can affect parameters of HRQL such as
physical function, social function, or mental health
functioning [1].
Patient-reported outcome measures such as
HRQL may provide better information, both posi-
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tive and negative, about the actual impact of ther-
apy on the patient’s life than more objective or
traditional clinical measures. HRQL measures pro-
vide a patient perspective on the impact of the dis-
ease and its treatment on the patient’s daily life
and functioning. Additionally, HRQL may pro-
vide more relevant information to third-party pay-
ers and patients making decisions regarding the
use of a therapy. The pharmaceutical industry would
like to be able to use patient-reported outcome
data, including HRQL data, on drug labels and in
promotional campaigns. As a result of increased
interest in health-related quality of life, there has
been an effort to provide guidance to researchers,
particularly the pharmaceutical industry, on the
conduct of HRQL research.
The Federal Food, Drug, and Cosmetic Act
(FFDCA) Section 505(d) defines evidence of effec-
tiveness of new drugs as follows: “. . . substantial
evidence [of drug effect] means evidence consisting
of adequate and well-controlled investigations.”
Health-related quality-of-life research fits within this
definition of substantial evidence [2]. In the con-
text of an approved label for a drug, a single, well-
controlled, clinical trial of HRQL could constitute
a labeled claim for improvement in HRQL. Stan-
dards for the assessment and inclusion of HRQL
data as a patient-reported outcome measure on
labeling and in promotional campaigns are not
currently available. To assist in the development
of guidance on HRQL measures and research, a
workshop on regulatory issues for HRQL was held
on March 24 and 25, 1999. The workshop was
planned jointly by the members of the Pharma-
ceutical Research and Manufacturers of America
Health Outcomes Work Group (PhRMA HOWG,
now called the PhRMA Health Outcomes Com-
mittee [PhRMA HOC]) and the Division of Drug
Marketing, Advertising, and Communications of
the Food and Drug Administration (DDMAC FDA).
To facilitate discussion, the workshop was limited
to six primary regulatory issues dealing with health-
related quality-of-life measures collected in clinical
trials of pharmaceutical therapies.
The workshop included introductory presenta-
tions by experts to provide an overview of the cur-
rent state of HRQL for each of the six issues out-
lined in Table 1. Among the topics discussed was
the relationship of HRQL and safety assessment. A
consensus position that HRQL is a measure of ef-
fectiveness was agreed to before the meeting. While
it can be argued that HRQL can be used to mea-
sure both bother and tolerability associated with a
disease or a treatment, the group felt that HRQL
measures were not developed for, nor should they
be used for, detection of safety problems, and that
HRQL measures are not a substitute for collection
of spontaneously reported adverse events. Individ-
ual questions or overall scores may be sensitive to
and inform about safety issues. However, they re-
flect events and effects without attribution and as
such should not require review or individual report-
ing with the aim of “signaling” safety problems.
HRQL when used as a research measure should be
accompanied by all customary protocol-driven pro-
tections and monitoring of safety as is done for
any other effectiveness measure. In some cases, re-
searchers have excluded specific questions from
validated HRQL questionnaires in order to avoid
including questions that may deal with adverse
events (e.g., the Sickness Impact Profile asks about
suicidal ideation). However, this invalidates the
instrument or, at a minimum, the domain. There-
fore, in most cases the complete validated measure
should be used, although exceptions to this rule
may be appropriate.
Separate work groups were convened for each
of the remaining five issues. Table 2 lists the five
work groups and the primary purpose of each.
Work-group participants were representatives of
 
Table 1
 
Introductory presentations
 
Title of presentation Speaker Affiliation
What constitutes health-related quality of life for 
labeling and promotion?
Nancy Kline-Leidy, PhD, RN Health Outcomes Research MEDTAP, International
Instrument selection: How much is enough? Dennis Revicki, PhD Health Outcomes Research MEDTAP, International
Collection of HRQL data: Are there special 
considerations for study design?
Albert Wu, MD, MPH School of Hygiene and Public Health
Johns Hopkins University
Analysis of HRQL data: Are there special 
considerations for analysis?
Lisa Kammerman, PhD Division of Biometrics, Center for Drug Evaluation 
and Research, Food and Drug Administration
Interpretation of HRQL: What does it mean? Geoffrey R. Norman, PhD Clinical Epidemiology and Biostatistics
McMaster University
HRQL and safety: How are they related? Hugh Tilson, MD, DrPH Health Affairs Glaxo Wellcome, Inc.
HRQL and the FDA: What can we say? Laurie Burke, RPh, MPH Managed Care Outcomes and Labeling Staff
Food and Drug Administration
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the pharmaceutical industry and FDA who were
interested in health-related quality-of-life research.
Each participant either chose (based on interest)
or was assigned to (based on need to balance
groups) one of the five work groups. Two facilita-
tors were assigned to lead and record each group’s
discussions. Guidelines for facilitating participa-
tion and discussion were identified and used, and
each work-group facilitator followed the format
outlined in Table 3.
Facilitators reviewed the objectives for the
work-group participants. Work-group members
were asked to brainstorm to develop a list of items
on each issue. After assembling a list of issues,
participants voted to determine priority items and
narrow the selection to those items that the major-
ity of participants identified as being of primary
importance. Once the primary items were identi-
fied, facilitators proactively solicited input from
each participant to ensure that all viewpoints were
being considered. The current state of HRQL re-
search, the impact of the current state, and the de-
sired state were discussed for each issue. This pa-
per summarizes the issues and discussions regarding
the current state for each issue and regulatory rec-
ommendations from each of the five work groups
of this workshop pertaining to health-related
quality of life. It is important to recognize that the
recommendations reached by the work groups do
not represent FDA policy but rather are a consen-
sus of the various work groups.
 
Work Group 1: Instrument Selection and
Validation Workshop
 
Purpose: to discuss selection, development, and
validation of health-related quality-of-life measures
for use in clinical trials of pharmaceutical thera-
pies.
The work group identified the following five
key issues pertaining to instrument selection and
validation:
1. What are minimally acceptable standards of
evidence for validity and reliability in health-
related quality-of-life measures?
2. Can the same clinical trial data be used for in-
strument validation and measurement of treat-
ment effects?
3. Should the same standards of evidence be ap-
plied to previously developed, well-accepted in-
struments as well as newly developed and vali-
dated instruments?
4. What is an acceptable or unacceptable relation-
ship between clinical and health-related qual-
ity-of-life measures?
5. What standards should be used to decide
whether to use a disease-specific and/or general
health-related quality-of-life instrument in a
clinical trial?
 
What are minimally acceptable standards of ev-
idence for validity and reliability in health-
related quality-of-life measures?
 
The workshop
participants recommended that guidelines request
that any promotional use of HRQL measures in-
clude a description of methods used to evaluate the
measurement characteristics of specific HRQL
measures. This description could include such vali-
dation measures as reliability, construct and dis-
criminant validity, and responsiveness as appropri-
ate and known within the context of the disease,
study population, and use of the measure. The de-
scription could be in the form of a footnote or as a
 
Table 2
 
Health-related quality-of-life work groups
 
Work groups Purpose of work groups
Instrument selection and validation
Study design 
Data analysis
To discuss selection, development, and validation of health-related quality-of-life measures for 
use in clinical trials of pharmaceutical therapies. To discuss clinical trial study design issues 
related to planning trials of pharmaceutical therapies conducted to evaluate measures of 
health-related quality of life.
Interpretation of clinical meaning in 
Health-related quality-of-life measures
Purpose: to discuss analytic issues related to health-related quality-of-life measures collected in 
clinical trials of pharmaceutical therapies.
Promotional use of health-related quality- 
of-life results
Purpose: to discuss issues related to definition and calculation of clinically meaningful changes and 
differences in health-related quality of life measures within clinical trials of pharmaceutical 
therapies. To discuss promotional use of health-related quality-of-life measures from clinical 
trials of pharmaceutical therapies.
 
Table 3
 
Organization of workshop groups
 
Introductions and objectives
Identify and prioritize key issues
Develop problem statements
Current state
Impact
Desired state
Develop technical recommendations
Present results to workshop
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reference in the promotional piece to provide infor-
mation dealing with validation of the measure.
It was clear from the discussion that there is no
clear consensus among researchers or the FDA re-
garding acceptable standards for validation or and
use of instruments that will allow HRQL claims to
be included in promotion and advertising. In gen-
eral, HRQL measures have been developed and
validated more rigorously than many physician-
assessed clinical measures or patient-completed clin-
ical measures. The literature provides some guid-
ance in terms of evaluating HRQL measures for
reliability and validity [3–11]. The generally ac-
cepted level for intraclass correlation coefficients
for test-retest reliability is 0.7 or greater. How-
ever, this may not apply to certain diseases that
are not stable or that vary over time, and some
measures may not be suitable for evaluation of
test-retest reliability. Validation needs to be un-
derstood within the framework of a disease, a pop-
ulation, and the use of the measure because the
validity of an HRQL measure may vary among
diseases and populations. The measurement char-
acteristics of HRQL measures need to be under-
stood in a manner similar to any other measure of
disease and treatment. A clinical test (such as blood
pressure or cholesterol level) that does not show
good test-retest reliability, validity, or responsive-
ness could not be used to assess disease status or
response to therapy.
The work group recommended that descriptive
(rather than prescriptive) guidelines for what con-
stitutes validity of HRQL measures should be es-
tablished. That is, guidelines should not mandate
a minimally acceptable level of reliability or valid-
ity, but rather should request that the measure-
ment characteristics of the HRQL measure be de-
scribed. This would allow reviewers to determine
whether the measurement characteristics were well
understood within the disease and population in
which they were used. Furthermore, the work group
recommended that guidelines not provide a list of
acceptable HRQL measures.
 
Can the same clinical trial data be used for in-
strument validation and measurement of treat-
ment effects?
 
Use of clinical trial data for instru-
ment validation and measurement of treatment ef-
fects should be limited to only those situations in
which it can be clearly shown that treatment does
not affect item selection or validation.
When measuring HRQL within the context of a
clinical trial, there is often a desire to provide ad-
ditional information about the measurement char-
 
acteristics of an instrument by maximally using
the clinical trial data. Participants agreed that un-
der certain conditions, using the same trial data
for both validation and measurement would be ac-
ceptable, such as in the case where baseline mea-
surements are used to determine reliability. How-
ever, under other conditions this would not be
acceptable, such as in the case where a large pool
of possible items for an HRQL measure are in-
cluded in a clinical trial of a particular therapy
and items are subsequently selected to comprise a
final HRQL measure based on a potential benefit
associated with that treatment. In the former situ-
ation, only baseline data is being utilized for eval-
uation of an HRQL measure, whereas in the lat-
ter, item selection for HRQL measurement could
be biased in favor of the therapy being evaluated,
thereby creating a measure limited to only those
items for which the therapy has a positive effect. It
would be preferable to select items that are impor-
tant to patients regardless of the treatment re-
ceived. Data from early-phase clinical trials may
be useful in determining the validity, and particu-
larly the responsiveness, of HRQL instruments to
be used in later trials. Guidelines could provide a
comprehensive set of situations that would more
broadly demonstrate the limits of acceptability.
 
Should the same standards of evidence be applied
to previously developed, well accepted instru-
ments as well as newly developed and validated
instrumentation?
 
A description of the development
methods and measurement characteristics (e.g., reli-
ability, validity, and responsiveness) should be pro-
vided for all instruments, both new and old.
It was recognized that familiarity with old, com-
monly used instruments imparts a degree of credi-
bility that may not be justified. A description of the
development methods and validation procedures
should be provided for all measures of HRQL, in-
cluding well-established instruments. If a set of
minimally acceptable standards of evidence has
been developed, all instruments should be required
to meet these, and use of those instruments that do
not meet such standards, even if they have been in
routine use, should be discouraged.
 
What is an acceptable or unacceptable relation-
ship between clinical and health-related quality-
of-life measures?
 
HRQL measures provide addi-
tional information beyond that obtained with
more traditional clinical measures such as physi-
cian assessments and physiologic, anatomic, and
laboratory measures. In cases where the relation-
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ship between clinical measures and HRQL is dis-
cordant, regulatory review has generally accorded
greater credibility to clinical measurements than
to measurements of HRQL.
Patient-reported outcome measures such as
HRQL are not surrogate measures for more tradi-
tional clinical measures such as physician assess-
ments and anatomic, physiologic, and laboratory
measures. Rather, HRQL measures provide addi-
tional information regarding efficacy, and some-
times tolerability, and ways in which a therapeutic
intervention affects the lives of patients from the
patient’s perspective. HRQL assessments may deal
with the impact of disease and therapy and their
combined effect on certain aspects of patients’
quality of life such as social, emotional, physical,
and cognitive functioning that cannot be collected
with more traditional clinical or tolerability mea-
sures. Wilson and Cleary propose a conceptual
model that integrates biological and physiological
(or clinical) factors with other measures of health
such as symptoms, function, health perceptions
and quality of life [1].
Results of an HRQL measure may or may not
be consistent with other clinical measures depend-
ing on the disease state and the therapy. There was
agreement that in the current hierarchy of inter-
pretation, when there is discordance between a
clinical measure and an HRQL measure, the HRQL
measure has generally been regarded as secondary.
It was not expected that a perfect relationship
between a clinical outcome and a quality-of-life
measure would exist, but it was generally expected
that the HRQL and clinical measures should not
be in conflict if a health-related quality-of-life claim
were to be used. The issue of conflicting outcomes
could exist even when a validated HRQL instru-
ment is included in certain clinical outcomes (e.g.,
positive quality-of-life results with negative mor-
tality). It was recognized that clinical measures of-
ten prevail over HRQL in terms of regulatory re-
view, and that the field would need to mature
before an HRQL measure would take precedence
in these circumstances.
 
What standards should be used to decide
whether to use a disease-specific and/or general
health-related quality-of-life instrument in a
clinical trial?
 
Regulatory guidance should not man-
date that both general and disease-specific mea-
sures be used in the same clinical trial. Rather, the
most appropriate HRQL measure(s) should be se-
lected based on knowledge of available disease-
specific measures, the degree of validation of both
general and disease-specific HRQL measures in
the population to be studied, and the feasibility of
implementing the HRQL measure.
Health-related quality of life can be measured
with validated general HRQL instruments in most
diseases and with disease-specific instruments in
other cases. However, in many clinical trials, a
general HRQL measure is not specific enough to
detect the impact of the intervention. The work-
shop participants advised against a mandate for
the use of a general or a disease-specific instru-
ment for all disease categories. The availability of
validated instruments for the population under
study should drive each case. In certain situations,
it may be desirable to use both general and dis-
ease-specific instruments in the same study. Cases
in which a general measure may be useful could
include trials of chronic diseases where long-term
treatment may have delayed benefits or side ef-
fects, where the evidence for the validity of a dis-
ease-specific instrument is less than optimal, or
where it is known that a general measure is re-
sponsive and captures most of the domains af-
fected by a disease or therapy. Which measure(s)
to use should be determined on an individual trial
level based on availability of validated instru-
ments, knowledge of performance characteristics,
the disease, population, duration of the trial, and
feasibility of implementing the HRQL instrument.
 
Work Group 2: Study Design
 
Purpose: to discuss issues related to the design of
clinical trials of pharmaceutical therapies aimed at
evaluating health-related quality of life.
 
What elements should be considered when de-
signing clinical trials to assess health-related
quality of life?
 
HRQL trials are frequently de-
signed and conducted without adequate preplan-
ning and thought to achieving an HRQL claim.
This often means that the HRQL hypotheses, an
HRQL data analysis plan, the meaning of HRQL
differences, and HRQL data-handling issues may
not be specified in the protocol. In addition, the
rationale for selection of the HRQL instrument(s)
in the study is often not provided.
Work-group participants recommended that
clinical trials of HRQL be incorporated into the
clinical development plan. The work group be-
lieved that clinical research standards that are well
documented in the scientific literature should be
applied to HRQL trials. The rationale for instru-
ment selection should be provided in the protocol
 Workshop on HRQL Regulatory Issues
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along with a discussion of meaningful change to
be detected by the instrument.
A fundamental issue regarding use of HRQL
data in labeling and promotion of drug products is
whether the trials that produce such data have
special design considerations. Many traditional
clinical trials attempt to generate data to answer
the research question, Is treatment A better than
placebo (or treatment B) as measured by clinical
end points? The end points in such trials are typi-
cally mortality, disease markers, physician- or
patient-assessed signs and symptoms, and/or labo-
ratory or physiologic abnormalities. There is a
tradition of conducting clinical trials to compare
treatment interventions using these end points. The
literature regarding HRQL study methodology for
use in clinical trials is less comprehensive.
Frequently, HRQL measures are included in a
clinical trial that has been designed to detect changes
in a traditional clinical (anatomic or physiologic)
end point. It is asserted that because clinical trials
are expensive and time-consuming, this “piggy-
backing” of HRQL measures may be an efficient
use of resources. Including HRQL measures in this
way, however, may produce scientific difficulties
with the use of the HRQL data. For example,
HRQL hypotheses, an HRQL data-analysis plan,
the meaning of HRQL differences, and HRQL
data-handling issues may not be specified in the
protocol. In addition, the inclusion criteria of the
trial may be based on clinical end points only. Pa-
tients will thus be selected who will respond to the
treatment as measured by the clinical end point
but who may not have impairments in HRQL
scores. The duration of the trial may be designed
to increase the chances of detecting clinical changes.
The time required to detect changes in HRQL may
be different from the time required for clinical
changes, or lack thereof, to be recognized or man-
ifested. Moreover, the selection of instrument(s) to
measure HRQL can often be based on availability
only and may be unrelated to the intervention or
the intended clinical outcomes of the study.
The work group agreed that HRQL should be
included in the clinical development plan. This
whould ensure that proper consideration is given
to issues dealing with HRQL claims to be ad-
dressed in the trial. Furthermore, it was agreed
that design standards for clinical trials should be
applied to trials designed to support HRQL claims.
For example, pre-specification of HRQL hypothe-
ses, data analysis, data handling and meaningful
changes of the HRQL measures should be included
in the protocol. This could also be accomplished
 
by designing a separate protocol to address HRQL
or other secondary outcome measures.
HRQL trials that are intended for promotional
or labeling use should be designed with the in-
tended HRQL claim(s) in mind. In these trials, pa-
tients who have impairments in HRQL, as measured
by the HRQL instrument used in the trial, should
be selected. The duration of the study should be
designed to allow the detection of HRQL changes
by the instrument used. The sample size should be
large enough to detect statistically significant dif-
ferences between treatments as measured by the
HRQL instrument. Finally, sound rationale for
the selection and timing of administration of the
HRQL instrument should be provided in the pro-
tocol. This rationale should include considerations
such as the sensitivity of the instrument, disease
state, population to be studied, goals of the study,
treatment intervention, and time period for mea-
suring the instrument.
 
Work Group 3: Study Analysis
 
Purpose: to discuss analytic issues related to
health-related quality-of-life measures collected in
clinical trials of pharmaceutical therapies.
In terms of labeling and advertising of prod-
ucts, the analysis of HRQL outcomes data should
meet the same standards as other clinical out-
comes considered for claims. The analysis of
HRQL should be specified as part of the overall
statistical analysis plan and be in accordance with
sound statistical principles. The analysis plan should
specify the objectives and hypotheses, sample size
calculations, method of analysis including the han-
dling of missing data, and adjustments for multi-
ple testing. Simplicity of analyses should be the
rule when appropriate.
The work group identified the following three
key questions regarding analysis of HRQL data:
1. How should multiple comparisons of pre-spec-
ified health-related quality-of-life scale(s) or
domain(s) be handled?
2. What are acceptable methods to deal with poten-
tial biases from missing data (unit nonresponse)?
3. What approaches should be used for the analy-
sis of longitudinal HRQL data?
 
How should multiple comparisons of pre-specified
health-related quality-of-life scales or domains
be handled?
 
It was recommended that protocols
should pre-specify use of one of the accepted
methods for controlling Type 1 errors (e.g., O’Brien,
step-down) by limiting the number of key end
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points for statistical testing and analysis or by us-
ing summary measures when appropriate.
Univariate tests of each health-related quality-
of-life scale and each time point can seriously in-
flate the Type I (false-positive) error rate. One so-
lution proposed for handling the issue of multiple
comparisons is to specify a priori three or fewer
key end points for statistical testing and analysis.
The use of summary measures (global statistics)
such as area under the curve and O’Brien’s method
[12] should be considered when appropriate. The
analyses of the remaining scales or time points,
which do not require a adjustment for multiplic-
ity, can be designated as secondary and explor-
atory or can be presented descriptively and graph-
ically. An alternative method to address the problem
of multiple comparisons is to use one of the ac-
cepted multiple-comparison methods for control-
ling the experimental error rate. These include
step-down procedures, global or composite assess-
ment measures (e.g., O’Brien’s methods), adjust-
ment methods for Type 1 error (e.g., Holm’s se-
quential rejective Bonferroni procedure), 
 
p
 
-value
adjustment methods (e.g., Westfall and Young’s
adjustment), and critical value adjustments (e.g.,
Tukey, Ciminera, and Heyse’s adjustment). The
relevance and use of multiple comparison methods
in different scenarios are documented elsewhere
[13–18].
 
What are acceptable methods to deal with po-
tential biases from missing data (unit nonre-
sponse)?
 
Missing data may involve data that are
missing for certain patients or items that are miss-
ing within a domain or scale. For missing HRQL
data from patients, several recommendations were
given: Prospectively document reasons for missing
data, collect covariates to help analyze the missing
data pattern, conduct sensitivity analyses with dif-
ferent models or strategies, and pre-specify the use
of existing methods such as complete case analy-
sis, available case analysis, summary measures,
maximum likelihood-based approaches, or impu-
tation approaches. For missing data within a do-
main or scale, the data analysis plan should ad-
dress how measures will be scored in the event of
missing data.
The main cause for concern regarding missing
data is the potential for bias. Bias affects the inter-
pretation of data, and the results of the trial be-
come questionable. In the case of unit nonre-
sponse, where all items on a scale are missing for a
subject, HRQL data should be analyzed in differ-
ent ways (sensitivity analyses) and confident con-
clusions made only when consistency is achieved.
Several methods exist for unit nonresponse when
assessments are collected over time. One method
[15] involves a description of individuals with
nonmissing data and missing data at each time as-
sessment, along with the reasons for missing data.
It is advisable to collect additional covariates such
as subjects’ survival status, disease status, and
number of completed assessments. This informa-
tion can be combined with a graphical representa-
tion of subjects with different numbers of com-
pleted assessments to observe whether patterns of
change over time are comparable.
Two methods have been routinely applied to
analyze missing data: in a complete case analysis,
only subjects with data at all relevant time assess-
ments are analyzed; in an available case analysis,
subjects with data on a certain variable at any as-
sessment are the cohort analyzed. These two
methods are best used when cases left out of the
analysis can be assumed to be similar to those in-
cluded; i.e., cases are missing completely at ran-
dom. Another method to be considered uses a
summary measure (e.g., the mean) that reduces the
data over time of each subject into a single sum-
mary measure that reflects some important aspect
of response. Maximum likelihood-based statistical
approaches to the analysis of missing data, which
use all the available data, should be considered as
well. These approaches include analysis of re-
peated measures using mixed-model analysis of
variance that incorporates noninformative missing
data (i.e., missing at random) and allows for com-
parisons of treatment by time interactions. For
missing data that is informative (i.e., not missing
at random), selection models and pattern-mixture
models are two recommended techniques when
there is evidence that subjects have stopped filling
out quality-of-life forms because of side effects,
disease progression, or therapeutic effectiveness.
Methods of imputation, which may be used for
cross-sectional and time-series data, may also be
valuable. These methods include mean imputa-
tion, last observation carried forward, regression
imputation, hot deck imputation, and multiple im-
putation, of which the last two are likely to show
the most promise. Missing data that are imputed
would complete a data set(s) that in many cases
could then be analyzed using standard statistical
methods (e.g., analysis of covariance). Determina-
tion of what methods are appropriate or accept-
able depends on distinguishing the pattern of
missing data and identifying a mechanism to gen-
erate the missing data. The continued develop-
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ment of easy-to-use software was encouraged to
implement these techniques and examine their suit-
ability.
In situations where data on specific items
within a domain or scale is missing because of pa-
tient nonresponse, the data analysis plan should a
priori specify how the domains or scales will be
scored if items are missing. As an example, if there
are five items in a scale, the data analysis plan
should indicate that a minimum of three item re-
sponses are required to calculate a scale score.
More detailed information about the suitability
of different methods for handling missing data in
different contexts is documented elsewhere [16].
 
What approaches should be used for the analysis
of longitudinal HRQL data?
 
Appropriate meth-
ods for analysis of longitudinal data exist and
should be described a priori.
The choice of an appropriate method for analy-
sis of longitudinal HRQL data depends, in part, on
the nature of the missing data and number of multi-
ple end points and comparisons. Two basic ap-
proaches were considered for analysis of longitudi-
nal data. The first was analysis of variance of
repeated measures, which includes multiple univari-
ate analyses and multivariate analyses. Multiple
univariate analysis involve an analysis at each time
point or specified time points and includes proce-
dures such as a 
 
t
 
-test, an analysis of variance, or a
Wilcoxon rank-sum test. These analyses should be
considered when the number of tests is small and
interest centers on a particular time assessment.
Multivariate analyses captures the richness of lon-
gitudinal data over repeated time assessments. It in-
cludes multivariate analysis of variance when the
proportion of missing data is small. It also includes
growth-curve modeling and mixed-model analysis
of variance to be considered when data are missing
at random and pattern-mixture models and selec-
tion models when data are not missing at random.
The second approach to analyzing longitudinal
data is to reduce missing data and multiple testing
[17] to calculate a single summary measure, such
as the rate of change or area under the curve, for
each subject. Often, these summary measures can
then be analyzed by simple statistical techniques
such as analysis of variance as though they were
raw data. The statistical analysis plan, completed
before the data analysis phase of a study, should
include the analytic procedures to be used in han-
dling the longitudinal structure of the HRQL data.
Appropriate methods for longitudinal analysis ex-
ist and depend on the research questions of inter-
est as well as on the influence of missing data and
multiple testing.
In summary, the same standards of statistical
analysis used for clinical measures also apply to
HRQL measures with respect to the three key ana-
lytic issues: multiple comparisons, missing data,
and longitudinal analysis. For each issue, the choice
of an acceptable method depends on the situation.
This section prioritized the analytic issues and
highlighted potential solutions. Although it is be-
yond the scope of this summary report to detail
the methods themselves, an experienced statisti-
cian can explain the advantages and disadvantages
of each method in a given situation. The references
cited in this section [12–18], along with their cita-
tions and other reports [19], can provide further
guidance.
 
Work Group 4: Interpretation of Clinical Meaning in 
Health Related Quality of Life
 
Purpose: to discuss issues related to definition and
calculation of clinically meaningful changes and
differences in health-related quality-of-life measures
within clinical trials of pharmaceutical therapies.
The group identified approximately 20 issues
relevant to the topic of how to interpret HRQL
scores. Two issues of primary importance were
chosen and were discussed in depth: 1) whether
the interpretation of HRQL should be different
from any other subjective clinical measure; and 2)
that the current research methods used to estimate
minimal important difference have been shown to
have methodological flaws [20].
 
Should the interpretation of HRQL be differ-
ent from any other subjective clinical measure?
 
HRQL measures should be regarded as equivalent
to any other clinical end point when determining
what constitutes a clinically important change
from baseline or difference between treatments.
Statistical significance should be used until ac-
cepted methodological approaches for minimal im-
portant difference are developed and accepted.
The interpretation of HRQL has received atten-
tion as the use of HRQL measures in clinical trials
has grown. Currently, minimal important differ-
ence is relevant for HRQL interpretations because
the FDA would like to know how to judge changes
due to drug treatment within groups and/or differ-
ences observed between groups. The work group
acknowledged that it is important to be able to
provide some assistance with the interpretation of
HRQL measures. Consumers and health-care de-
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cision makers need to understand the meaning of
change in clinical measures and in HRQL mea-
sures to make informed decisions about treatment.
Furthermore, it was generally agreed that the in-
terpretative methods for HRQL are not well de-
fined although they are probably no worse off
than many other subjective, or in some cases ob-
jective, clinical measures. Currently, what consti-
tutes a clinically important change from either
baseline or difference from placebo of many tradi-
tional clinical measures is not well understood ex-
cept when related to a life-threatening condition.
One definition might be that the clinically impor-
tant change is that magnitude of change or differ-
ence from placebo required for physicians to pre-
scribe a drug to patients. However, this magnitude
may vary depending on the type of physician and
on his or her interpretation of the change or dif-
ference as being important. HRQL measures are
more challenging to interpret than some clinical
measures because there is no standard metric for
all HRQL instruments, unlike, for example, those
that measure blood pressure and report results in
mmHg or measure cholesterol and report results
in mg/dl. Additionally, more than 40 years of epi-
demiological data demonstrate the impact of treat-
ing blood pressure and/or cholesterol on morbidity
and mortality end points and assist in understand-
ing the implications of a change of 3 mmHg in the
diastolic blood pressure or of 5 mg/dl in free cho-
lesterol for patients as a group. In contrast, mea-
surement standards and metrics for HRQL measures
vary by instrument, and the meaning of improving
the score on a group mean scale by 0.5 or by 10%
is not well understood.
In an attempt to address the issue of how to in-
terpret a certain level of change in an HRQL in-
strument, some HRQL instrument developers have
published the estimated minimal (clinical) impor-
tant difference for their instrument. An example of
this is the Juniper et al. [21,22] Asthma Quality of
Life Questionnaire (anchoring to a global question
of change for an uncontrolled asthma group that
experienced change) or the Short Form 36 Health
Survey (providing normative values for different
populations and diseases) [23]. Others have adapted
these methods and estimated minimal important
difference using various methodological approaches
for existing instruments. This is appealing from a
pragmatic perspective because it allows easy deter-
mination of whether the change is meaningful.
However, in some cases the FDA has rigidly ad-
hered to these published cut points; e.g., if the esti-
mated minimal important difference is 0.5, a change
of 0.49 is not considered relevant. This rigidity
may lead to inappropriate interpretation of the
data and implies the cut points have no variance.
In other cases, a cut point calculated as a change
from baseline has been interpreted as meaning a
difference between groups or a difference from
placebo that is not supported by the methodology
used to determine the cut point. The appropriate-
ness of using specific cut points was questioned.
One option would be to recognize that the cut
points are associated with a certain degree of vari-
ance and that a certain degree of flexibility with
respect to those cut points is justified. The mini-
mal important difference may also differ depend-
ing on the starting point of a scale. An instrument
for benign prostatic hypertrophy was used as an
example wherein the minimal important differ-
ence depended on the patient’s global classifica-
tion of mild, moderate, or severe disease.
There is also a certain degree of confusion with
respect to the minimal important difference for
group differences versus individual differences. A
difference of less than one point for a group may
be considered unimportant, whereas the smallest
amount of clinically meaningful change on a Lik-
ert-type scale for an individual would need to be
at least one point. For diseases where the patient’s
perception of change in HRQL can be measured,
each individual patient decides if a therapy is pro-
viding a clinically meaningful change within the
context of efficacy, safety, and cost for him/herself
by either continuing on therapy or discontinuing
therapy.
The impact of inconsistent handling of HRQL
data relative to other measures of clinical effec-
tiveness creates confusion regarding where HRQL
as a measure stands relative to other measures and
how to interpret the data.
A change in HRQL can be a component of a
risk-to-benefit decision that would also include
safety, efficacy, and cost. If one measures efficacy
alone, then any improvement is good. The work
group recommended that the risk-to-benefit ratio
for a drug be analyzed. HRQL results also need to
be understood within the context of other clinical
trial results. Other measures of efficacy and safety
should be consistent with what is found with an
HRQL instrument.
The work group’s recommendation is to treat
HRQL as any other clinical end point to determine
what constitutes a clinically important change or
difference between groups. That is, statistical signif-
icance should be used until good methodological
approaches for minimal important difference are
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established. Another option would be to use confi-
dence intervals as a means of expressing results.
 
The current research methods to estimate mini-
mally important clinical difference have been
demonstrated to have methodological flaws.
 
A
multidisciplinary research group should be man-
dated to develop a research process to establish
scientifically sound and widely accepted methods
for determining what constitutes a minimal im-
portant difference for clinical measures.
The second issue, which is closely related to
the first issue regarding HRQL interpretation, is
that current research methods to estimate mini-
mal important difference have been shown to
suffer from certain methodological flaws. It is ap-
parent that the current terminology requires con-
sistency and understanding. The group felt that
while the terms are used at times interchange-
ably, minimal important difference (MID), mini-
mal perceptible difference (MPD), and minimal
important change (MIC) all had different mean-
ings. There is a lack of obvious consensus with
respect to the methodological issues involved in
determining clinically relevant change or differ-
ence. Recent approaches that use retrospective
global assessments as an anchor are known to
have significant limitations.
The impact of this current state of affairs is that
decision makers are left with inaccurate estimates
of MID, which makes interpreting HRQL results
for drugs that fail to meet the MID but for which
statistically significant clinical differences were found
in comparison with placebo or an active compara-
tor confusing. The desired state would be to achieve
a sound, scientifically credible research process to
estimate and interpret the MID.
The work group’s recommendation is to estab-
lish a multidisciplinary research group to develop
a research process and be responsible for defining
and clarifying the terminology and establishing a
research agenda. A list of issues dealing with the
interpretation of clinical meaning was generated
for this multidisciplinary research group to re-
solve, and includes the following:
1. Define the perspective for minimal important
difference—patient, clinician, or third party.
2. Determine scientifically sound and widely ac-
cepted methods for determining MID.
3. Determine whether a gold standard should be
used to estimate MID. It was concluded that
use of a single-item global measure as a gold
standard would be fraught with psychometric
problems. Topics of discussion should include
 
what alternative measures could be used as
benchmarks in lieu of a global measure and de-
fining an MID for other clinical parameters, in-
cluding physiological measures and symptoms.
4. Determine whether MID should be measured
from baseline to study end within a group or
between two groups at study end.
5. Determine how the relevance of change in
HRQL fits into the context of change in the
other study measures. How consistent does
HRQL need to be with the primary end point if
it is a secondary end point, and vice versa?
6. Determine the clinical relevance of maintaining
HRQL, or of the attenuation of decline in HRQL.
How should lack of change be put in perspec-
tive? Is there a “negative” minimal important
difference such that no change is actually useful?
7. Determine whether global recommendations be
made regarding MID given disease differences.
8. Terminology suggestions: minimal perceptible
difference 
 

 
 patient perspective versus clini-
cally relevant change 
 

 
 physician perspective.
Given the lack of consensus regarding a research
approach and the methodological flaws in what is
currently accepted, the work group recommended
that no absolute standard for measuring MID be
imposed until additional research has been com-
pleted. One option discussed, but not adopted, was
to use effect size until consistency can be reached.
Another option discussed was to use case-by-case
evaluation. Because this seems to be the current
modus operandi, it did not seem appropriate to list
it as a recommendation.
 
Work Group 5: Promotional Issues
 
Purpose: to discuss promotional use of health-related
quality-of-life measures from clinical trials of
pharmaceutical therapies.
This workshop was divided into two groups based
on the interest manifested by workshop participants
to discuss promotional issues related to HRQL. The
two groups focused on four major issues:
1. Should HRQL results appear in approved la-
beling before being used in promotion, or is
HRQL promotion possible with two well-con-
trolled trials without mention in the label?
2. Should positive, neutral, and negative findings
all be presented in advertising and promotion,
or only positive ones?
3. What is the minimum disclosure regarding health-
related quality-of-life claims in promotion?
4. Should declared versus undeclared hypotheses
be disclosed in promotion?
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Should HRQL results appear in approved label-
ing before being used in promotion, or is HRQL
promotion possible with two well-controlled
trials?
 
HRQL promotion should be based on sub-
stantial evidence, consistent with existing promo-
tional guidelines.
Currently, inclusion in the label or “substantial
evidence” enables promotion. Both work groups
agreed that promotion should be allowed if HRQL
is in the label or supported by substantial evidence,
consistent with promotion of other efficacy param-
eters. One work group suggested that the FDA use
an outside advisory panel to conduct the reviews.
 
Should positive, neutral, and negative findings
be presented in advertising and promotion?
 
Full
results should be presented with fair balance to
positive, neutral, and negative findings and should
be consistent with pre-specified data-analysis plans.
The second issue concerns the presentation of
findings in promotion. The current state is not de-
fined, thus interpretation can be problematic. The
recommendation is to present the full range of re-
sults with fair balance and transparency. For ex-
ample, if a trial found that three of five domains
of a particular HRQL measure were positive and
two were neutral, promotion should clearly state
both the positive and neutral findings. However, a
priori hypotheses and operational definitions should
be provided to demonstrate that the findings on
specific domains were expected.
 
What is the minimum disclosure concerning
health-related quality-of-life claims in promo-
tion?
 
The HRQL instrument used needs to be dis-
closed and supported scientifically. Currently, there
is confusion in this area regarding the type of instru-
ment, representation of domain, effect size, and
manuscript citation. As a result there is a lack of un-
derstanding of what health-related quality of life re-
ally means. The work group supported the need for
clarity and minimum standards and recommended
that promotions report specifics concerning the mea-
surement characteristics of the HRQL instrument.
 
Should declared versus undeclared hypotheses be
disclosed in promotion?
 
Hypotheses should be stated
in advance and linked to domains where feasible.
The last major issue concerns the use of hy-
potheses. The work group noted that in the cur-
rent state the practice is variable. What is desired
are clear hypotheses, consistent policy between di-
visions, and clarity of direction with regard to
what the objectives of HRQL research. The group
recommended that HRQL researchers follow a
scientific approach by defining hypotheses that are
linked to domains and instruments.
 
Conclusions
 
A workshop format was utilized to generate regula-
tory issues for health-related quality-of-life (HRQL)
research. Each work group explored and listed nu-
merous regulatory issues for HRQL research. It
was beyond the scope of the work groups to at-
tempt to address every issue generated in detail be-
cause of time limitations. Therefore, facilitators
and participants were asked to prioritize and limit
the work-group dialogue to a few key issues for
more in-depth discussions and recommendations.
The work-group discussion included the current
state for each prioritized issue, the impact of the
current state, the desired state, and recommenda-
tions to achieve that desired state.
The work groups recommended that HRQL
measures and research be handled in a manner
similar to more traditional clinical measures and
research. In fact, it was noted that HRQL mea-
sures are often developed and validated with more
rigor than many traditional clinical measures.
However, it was also recognized that recognition
of and experience with HRQL measures by physi-
cians and researchers is more limited than for clin-
ical measures. The work groups anticipate that as
experience is gained with these measures and
methods, greater acceptance by physicians, regula-
tors, managed-care organizations, and other users
of health-care information will be achieved. Guid-
ance on the regulatory use of health-related qual-
ity-of-life results could be helpful to the industry
in overcoming some of the current uncertainty
concerning HRQL claims.
Consensus among members of the planning com-
mittee was reached before the workshop that HRQL
measures were not developed for, nor should they
be used for, detection of safety problems. Individ-
ual questions or overall scores may be sensitive to
and informative about safety issues; however, they
reflect events and effects without attribution and
as such should not be required to be reviewed or
individually reported for “signals” of safety prob-
lems. It was agreed that use of HRQL measures in
clinical research should require the inclusion of all
customary protocol-driven protections and moni-
toring of safety as is done with any other effective-
ness measure. Furthermore, excluding questions
about specific adverse events such as the Sickness
Impact Profile, which asks about suicidal ideation,
would invalidate the questionnaire, or at a mini-
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mum, the domain. Therefore, in most cases the com-
plete validated measure should be used.
Why is it important to provide guidance on how
health-related quality-of-life research is conducted?
Industry is interested in providing useful information
about the actual impact of pharmaceutical treat-
ments on patients and their lives, both in drug label-
ing and in promotion. Health-related quality-of-life
measures may provide more relevant patient-level in-
formation to third-party payers, physicians, and pa-
tients than traditional clinically oriented measures
that primarily address anatomic or physiologic as-
pects of disease and treatment. Currently, inclusion
of HRQL information in drug labels and in promo-
tion is limited because of concerns about how the re-
search has been conducted. The work groups clearly
advised that any recommendations regarding HRQL
measures and research should provide a guide rather
than a prescription on how to conduct research or
which HRQL instruments are acceptable, and they
recommended that HRQL measures be treated in the
same way as any other clinical end point. Addition-
ally, the work groups recognized that research in
HRQL methods is ongoing and that any guidance
should be flexible enough to allow for changes in the
field. Although members of the FDA participated in
the organization of the meeting and in the work
groups, it is important that any recommendations
that resulted from this workshop not be interpreted
as FDA policy, but rather, as a consensus on each is-
sue reached by members of the work groups.
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